menu
    • menu

    Company profile for Complement Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry ag...
    Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Complement Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    4th Floor, Central Working White City Translation and Innovation Hub 84 Wood L...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://complementtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/complement-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Complement Receive IND Clearance to Advance CTx001 into Opti-GAIN
    Complement Receive IND Clearance to Advance CTx001 into Opti-GAIN

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/complement-therapeutics-receives-fda-ind-clearance-to-advance-ctx001-into-opti-gain-a-phase-iii-clinical-trial-in-geographic-atrophy-secondary-to-amd-302577045.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share
    Dianthus Therapeutics Completes Enrollment Ph 2 Trial of DNTH103
    Dianthus Therapeutics Completes Enrollment Ph 2 Trial of DNTH103

    05 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/05/3073910/0/en/Dianthus-Therapeutics-Completes-Enrollment-of-Phase-2-MaGic-Trial-of-DNTH103-in-Generalized-Myasthenia-Gravis-With-Top-Line-Results-Expected-in-September.html

    GLOBENEWSWIRE
    05 May 2025
    Share Share
    Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer
    Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer

    03 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/complement-therapeutics-appoints-dr-parisa-zamiri-md-as-chief-medical-officer-301892499.html

    PR NEWSWIRE
    03 Aug 2023
    Share Share
    Complement Therapeutics Secures €72 Million in Series A Financing
    Complement Therapeutics Secures €72 Million in Series A Financing

    17 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/complement-therapeutics-secures-72-million-in-series-a-financing-to-advance-novel-therapies-targeting-complement-mediated-diseases-301798303.html

    PR NEWSWIRE
    17 Apr 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search